Clinical Investigation of Galnobax® for the Treatment of Diabetic Foot Ulcers
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01113515 |
Recruitment Status
: Unknown
Verified April 2015 by Novalead Pharma Private Limited.
Recruitment status was: Active, not recruiting
First Posted
: April 30, 2010
Last Update Posted
: April 15, 2015
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Diabetic Foot Ulcer | Drug: Esmolol hydrochloride Drug: Placebo gel | Phase 1 Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 50 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Triple (Participant, Care Provider, Investigator) |
Primary Purpose: | Treatment |
Official Title: | An Interventional, Placebo-Controlled, Randomized, Double-blinded Dose Comparison, Phase I/II Study to Determine the Safety and Efficacy of a New Gel Formulation of Esmolol Hydrochloride (Galnobax®) for the Treatment of Diabetic Foot Ulcer (DFU) |
Study Start Date : | February 2014 |
Estimated Primary Completion Date : | September 2015 |
Estimated Study Completion Date : | December 2015 |

Arm | Intervention/treatment |
---|---|
Placebo Comparator: Placebo
Placebo gel
|
Drug: Placebo gel
Other Name: Placebo control
|
Experimental: Galnobax 20% QD
Esmolol Hydrochloride (Galnobax) 20% gel once daily
|
Drug: Esmolol hydrochloride
Other Name: Galnobax-QD
|
Experimental: Galnobax 20% BID
Esmolol Hydrochloride (Galnobax) 20% gel twice daily
|
Drug: Esmolol hydrochloride
Other Name: Galnobax-20%
|
Experimental: Galnobax 14% BID
Esmolol Hydrochloride (Galnobax) 14% gel twice daily
|
Drug: Esmolol hydrochloride
Other Name: Galnobax-14%
|
- Safety outcome [ Time Frame: Till end of follow up period (Week 25) ]Incidence of adverse events (AEs) till end of follow-up phase
- Efficacy outcome [ Time Frame: Till end of treatment (Week 12) ]To evaluate the change from baseline in area and volume of ulcers at Week 12 and to compare the time taken for healing and closure of wound in different groups from baseline
- Pharmacokinetics [ Time Frame: Till end of treatment ]Pharmacokinetic profile of Galnobax® in subset of patients suffering from DFU

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 95 Years (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Subjects aged 18 to 95 years, inclusive, with Type 1 or Type 2 diabetes undergoing therapy for glycemic control
- Subjects having below knee ulcer of at least 4 week and maximum of 52 weeks duration which is a full thickness ulcer without exposure of bone, muscle, ligaments, or tendons
- Ulcer should be clinically non-infected
- Ulcer area (length x width) measurement between 1.5 cm2 and 10 cm2, inclusive and post debridement ulcer area less than or equal to 12 cm2.
- Full-thickness ulcer of Grade 1 or Grade 2 as per Wagner's classification system
- Recently debrided ulcer (2 weeks prior to screening) and post debridement ulcer free of necrotic debris, foreign bodies, sinus tracts, tunneling, and undermining, comprised of healthy vascularized tissue as determined by the Investigator
- Inability to perceive 10 grams pressure using Semmes-Weinstein 5.07 monofilament in the peri-ulcer area
- Ankle Brachial index between 0.7 and 1.2
Exclusion Criteria:
- Actively infected ulcers with or without purulent discharge, ulcers with exposed bone or associated with osteomyelitis.
- Subjects having cellulitis, ischemic or gangrenous ulcers in the opinion of the Investigator
- Glycosylated hemoglobin (HbA1C) >12%
- Diagnosed and/ currently unstable hypotension, heart block, cardiac failure, and other cardiac complications
- Subject diagnosed with cancer undergoing chemotherapy
- Revascularization surgery 4 weeks prior to signing the ICF
- Renal failure as defined by serum creatinine >3.0 mg/dL or renal insufficiency requiring frequent dialysis
- Poor nutritional status as measured by serum albumin <3.0 g/dL
- Active Charcot or other structural deformity that would prevent adequate off-loading of the study foot

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01113515
United States, Rhode Island | |
VA New England Health Care Division | |
Providence, Rhode Island, United States, 02908 | |
India | |
S.L. Raheja Hospital | |
Mumbai, Maharashtra, India, 400016 | |
Deenanath Mangeshkar Hospital & Research Center | |
Pune, Maharashtra, India, 411004 | |
M V Hospital for Diabetes Pvt. Ltd. | |
Chennai, Tamil Nadu, India, 600 013 | |
Malaysia | |
Hospital Kuala Lumpur | |
Kuala Lumpur, Malaysia |
Principal Investigator: | Vickie R Driver, DPM FACFAS | Providence Veteran Affairs Medical Center, RI |
Responsible Party: | Novalead Pharma Private Limited |
ClinicalTrials.gov Identifier: | NCT01113515 History of Changes |
Other Study ID Numbers: |
Novalead-Galnobax-0210 |
First Posted: | April 30, 2010 Key Record Dates |
Last Update Posted: | April 15, 2015 |
Last Verified: | April 2015 |
Keywords provided by Novalead Pharma Private Limited:
Diabetic foot ulcer Diabetic wound chronic non healing ulcer |
Additional relevant MeSH terms:
Ulcer Diabetic Foot Foot Ulcer Pathologic Processes Diabetic Angiopathies Vascular Diseases Cardiovascular Diseases Leg Ulcer Skin Ulcer Skin Diseases Diabetes Complications Diabetes Mellitus |
Endocrine System Diseases Diabetic Neuropathies Foot Diseases Esmolol Adrenergic beta-1 Receptor Antagonists Adrenergic beta-Antagonists Adrenergic Antagonists Adrenergic Agents Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Physiological Effects of Drugs |